Venom immunotherapy: when to start, when to stop.
Over the past 25 years, major advances have been made in the diagnosis and treatment of insect sting allergy. Controlled clinical trials have demonstrated the efficacy of venom immunotherapy (VIT) in the prevention of subsequent systemic reactions in allergic individuals. We have refined our criteria for selection of patients for VIT. Studies on selections of venoms, rush immunotherapy, and interval between VIT injections have been performed. Finally, much work has been done to try to define criteria for the discontinuation of VIT.
Graft
D F
DF
Asthma and Allergic Diseases, Park Nicollet Clinic, Minneapolis, Minnesota 55416-2699, USA.
D000293:Adolescent; D000328:Adult; D000997:Antivenins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000517:prevention & control*; D007115:Immunization Schedule; D007167:Immunotherapy / Q000379:methods*; D007299:Insect Bites and Stings / Q000276:immunology / Q000628:therapy*; D008297:Male; D012680:Sensitivity and Specificity; D012882:Skin Tests
D000997:Antivenins